Bicocca Open Archive

Logo unimib boa
FALANGA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.929
AS - Asia 6.474
EU - Europa 4.492
SA - Sud America 1.191
AF - Africa 191
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 23.290
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.862
SG - Singapore 2.737
HK - Hong Kong 1.364
IT - Italia 1.174
RU - Federazione Russa 1.002
CA - Canada 957
BR - Brasile 899
CN - Cina 826
VN - Vietnam 657
IE - Irlanda 558
SE - Svezia 527
DE - Germania 475
FR - Francia 206
BD - Bangladesh 193
IN - India 170
GB - Regno Unito 139
AR - Argentina 106
AT - Austria 85
UA - Ucraina 79
ID - Indonesia 76
IQ - Iraq 67
MX - Messico 67
ZA - Sudafrica 59
TR - Turchia 51
NL - Olanda 46
FI - Finlandia 45
EC - Ecuador 43
PH - Filippine 42
PK - Pakistan 42
JP - Giappone 39
ES - Italia 38
CO - Colombia 34
SA - Arabia Saudita 34
KR - Corea 31
MA - Marocco 29
VE - Venezuela 27
PL - Polonia 24
UZ - Uzbekistan 22
CL - Cile 20
PE - Perù 20
PY - Paraguay 19
RO - Romania 19
TN - Tunisia 17
ET - Etiopia 16
DZ - Algeria 13
MY - Malesia 13
AE - Emirati Arabi Uniti 12
DK - Danimarca 12
KE - Kenya 12
NP - Nepal 12
UY - Uruguay 12
CH - Svizzera 11
JO - Giordania 11
BO - Bolivia 10
EG - Egitto 10
IL - Israele 10
CR - Costa Rica 9
OM - Oman 9
AU - Australia 8
KZ - Kazakistan 8
PT - Portogallo 8
AL - Albania 7
CZ - Repubblica Ceca 7
GR - Grecia 7
JM - Giamaica 7
LB - Libano 7
MU - Mauritius 7
PA - Panama 7
TH - Thailandia 7
DO - Repubblica Dominicana 6
HN - Honduras 5
KG - Kirghizistan 5
KH - Cambogia 5
PS - Palestinian Territory 5
GE - Georgia 4
IR - Iran 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
GA - Gabon 3
LY - Libia 3
RS - Serbia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BE - Belgio 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
EE - Estonia 2
GP - Guadalupe 2
HU - Ungheria 2
LT - Lituania 2
ML - Mali 2
MM - Myanmar 2
NE - Niger 2
NZ - Nuova Zelanda 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
Totale 23.269
Salva come PNG Salva come JPEG
Città #
Singapore 1.396
Hong Kong 1.347
Ann Arbor 981
Fairfield 850
Toronto 797
Ashburn 758
Dublin 553
San Jose 516
Woodbridge 417
Wilmington 376
Milan 372
Houston 368
Chandler 362
New York 361
Frankfurt am Main 333
Dallas 316
Princeton 312
Cambridge 286
Seattle 266
Chicago 254
Santa Clara 233
The Dalles 213
Ho Chi Minh City 209
Hanoi 170
Beijing 163
Los Angeles 153
Jacksonville 143
Altamura 140
Lawrence 140
Lauterbourg 136
Boardman 114
Rome 106
Moscow 87
São Paulo 83
Ottawa 81
San Diego 80
Council Bluffs 62
Buffalo 58
Nuremberg 51
Vienna 48
Andover 46
Jakarta 40
Orem 39
Shanghai 38
London 35
Falls Church 32
Helsinki 32
Hefei 31
Tokyo 31
Rio de Janeiro 30
Salt Lake City 29
Baghdad 28
Seoul 28
Phoenix 26
Guangzhou 24
Nanjing 24
Redmond 24
Brooklyn 23
Atlanta 22
Dearborn 22
Florence 22
Da Nang 21
Figino 21
Montreal 21
Tashkent 21
Brasília 20
Dong Ket 20
Johannesburg 19
New Delhi 19
Warsaw 19
Dhaka 18
Haiphong 18
Norwalk 18
Charlotte 16
Tampa 16
Cape Town 15
Chennai 15
Columbus 15
Turin 15
Amsterdam 14
Ankara 14
Belo Horizonte 14
Campinas 14
Hải Dương 14
Lahore 14
Addis Ababa 13
Denver 13
Elk Grove Village 13
Istanbul 13
Medellín 13
Paris 13
Poplar 13
Quito 13
Wuhan 13
Chengdu 12
Curitiba 12
Delhi 12
Guayaquil 12
Jinan 12
Lima 12
Totale 14.917
Salva come PNG Salva come JPEG
Nome #
A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit β3 impact breast cancer cell extravasation 324
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 320
Treatment of venous thromboembolism with tinzaparin in oncological patients 289
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 283
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer 268
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study 268
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 261
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 253
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 243
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study 239
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 238
Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation 236
Thrombin generation predicts early recurrence in breast cancer patients 228
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 222
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 215
ISTH interim guidance on recognition and management of coagulopathy in COVID-19 211
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 210
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 210
Proceedings of the Second “International Conference on Thrombosis and Hemostasis Issues in Cancer”. September 19-21, 2003. Bergamo, Italy 205
Clozapine-induced anemia: A case-report 202
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update 201
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 200
Hemostatic biomarkers in occult cancer and cancer risk prediction 198
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 193
DOACs and “newer” hemophilia therapies in COVID-19: Reply 193
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia 188
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 185
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment 185
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 183
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 183
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE 182
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary 181
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 180
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 179
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review 179
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 178
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 177
Laboratory haemostasis monitoring in COVID-19 177
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: Results of the prospective collaborative EPICA study 176
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery 176
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 176
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 174
THE HYPERCOAGULABLE STATE IN CANCER-PATIENTS - EVIDENCE FOR IMPAIRED THROMBIN INHIBITIONS 174
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 173
Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin? 168
V. Plasmaferesi terapeutica 168
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 165
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study 165
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine 164
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study 163
Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells 163
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera 162
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia 160
Procoagulant mechanisms in tumour cells 160
RECOMBINANT VERSUS HIGH-SENSITIVITY CONVENTIONAL THROMBOPLASTIN - A RANDOMIZED CLINICAL-STUDY IN PATIENTS ON ORAL ANTICOAGULATION 160
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 159
Molecular biomarkers of thrombosis in myeloproliferative neoplasms 159
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 159
Association of plasma Protein C and CCL18 levels with neurodegenerative measures in Multiple Sclerosis patients 158
Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia 156
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 154
Unbalanced plasma control of TxA2 and PGI2 synthesis in Vitamin E deficient rats 154
The mechanisms of cancer-associated thrombosis 153
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors 152
The effect of Vitamin E or selenium on the oxidant-antioxidant balance in rats 152
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH 151
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 151
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 149
Venous thromboembolism in the hematologic malignancies 149
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 149
Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps 148
INEFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH LOW-RISK THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC-UREMIC SYNDROME 148
Type and dose of heparin in Covid-19: Reply 148
Molecular basis for the relationship between thrombosis and cancer 147
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis 146
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation 146
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 146
Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH 145
The Italian START-Register on anticoagulation with focus on atrial fibrillation 145
Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates 144
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial 144
Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment 144
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 144
Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates 143
Hemostatic biomarkers in cancer progression 142
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study 142
External validation of the DASH prediction rule: a retrospective cohort study 142
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER) 140
Cancer and venous thromboembolism 138
Soluble stroma-related biomarkers of pancreatic cancer 138
Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: The HYPERCAN study 138
Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa - Italy, April 23-25, 2010. Preface. 138
Microparticles in tumor progression 137
Edoxaban for the treatment of cancer-associated venous thromboembolism 137
Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia 136
La coagulopatia indotta da trauma 136
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction 135
Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016 134
Risk of Venous Thromboembolism in Surgical Elderly Patients. 133
Thrombosis in myeloproliferative neoplasms 132
Totale 17.655
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.332
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.332
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.563 160 169 178 95 64 76 93 102 69 98 110 349
2022/20232.027 370 568 182 133 95 404 7 90 95 17 41 25
2023/20241.469 26 52 20 18 227 403 259 44 243 20 5 152
2024/20254.320 303 731 200 166 354 74 289 96 414 610 329 754
2025/20269.937 655 606 828 948 924 524 1.317 586 772 676 1.100 1.001
2026/2027142 142 0 0 0 0 0 0 0 0 0 0 0
Totale 23.973